A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the Clinical AI company today announces that, together with its U.S. based strategic partner Phesi Inc. ("Phesi"), the two
About Sensyne Health www.sensynehealth.com Sensyne Health plc Sensyne Health plc (LSE: SENS) is a clinical artificial intelligence company operating a unique business model - a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems. The company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers r emote patient monitoring and real-time decision-making systems for healthcare organizations and their patients. In life sciences, Sensyne analyses large complex anonymized data sets to help life sciences companies accelerate the development of new medicines. About MagnifEye About MagnifEye MagnifEye is Sensyne s proprietary cloud-based software application, available as both a smartphone app and a web application, that uses advanced, proprietary deep learning algorithms developed by the Company
Investegate |Sensyne Health PLC Announcements | Sensyne Health PLC: Issue of Shares and Total Voting Rights investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
12 March 2021 | 09:39am
StockMarketWire.com - Clinical AI technology company Sensyne has signed a £470,000 agreement with the Department of Health & Social Care (DHSC) to conduct the second stage of a pilot study of its MagnifEye technology for use with COVID-19 lateral flow diagnostic tests.
The MagnifEye system is a software application available as both a smartphone app and a web application, that uses a cloud-based deep learning algorithm to automate the reading and analysis of different diagnostic tests, including lateral flow tests.
The agreement with the DHSC follows an announcement made by Sensyne on 09 February 2021 that it had signed an exclusive licence and development agreement with Excalibur Healthcare Services Limited to apply MagnifEye for use with lateral flow rapid diagnostic tests.